Head-To-Head Analysis: Kaleido Biosciences (NASDAQ:KLDO) vs. LianBio (NASDAQ:LIAN)

Kaleido Biosciences (NASDAQ:KLDOGet Free Report) and LianBio (NASDAQ:LIANGet Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings and risk.

Valuation & Earnings

This table compares Kaleido Biosciences and LianBio’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kaleido Biosciences $1.10 million 0.00 -$95.48 million ($2.24) N/A
LianBio N/A N/A -$110.29 million ($0.81) -0.37

Kaleido Biosciences has higher revenue and earnings than LianBio. LianBio is trading at a lower price-to-earnings ratio than Kaleido Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Kaleido Biosciences has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500. Comparatively, LianBio has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Kaleido Biosciences and LianBio, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kaleido Biosciences 0 0 0 0 N/A
LianBio 1 1 1 0 2.00

LianBio has a consensus target price of $5.33, suggesting a potential upside of 1,695.74%.

Profitability

This table compares Kaleido Biosciences and LianBio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Kaleido Biosciences N/A N/A N/A
LianBio N/A -33.17% -30.19%

Insider and Institutional Ownership

81.6% of Kaleido Biosciences shares are held by institutional investors. Comparatively, 74.8% of LianBio shares are held by institutional investors. 9.0% of Kaleido Biosciences shares are held by company insiders. Comparatively, 7.6% of LianBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Kaleido Biosciences beats LianBio on 7 of the 10 factors compared between the two stocks.

About Kaleido Biosciences

(Get Free Report)

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

About LianBio

(Get Free Report)

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Receive News & Ratings for Kaleido Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kaleido Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.